Cited by 30Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryAdrenal Hormones and Disorders

THERAPY OF PRIMARY HYPOTHYROIDISM WITH L‐TRIIODOTHYRONINE: DISCORDANT CARDIAC AND PITUITARY RESPONSES

RIDGWAY, E. C., COOPER, D. S., WALKER, HARRIET, DANIELS, G. H., CHIN, W. W., MYERS, G., MALOOF, FARAHE·1980·Clinical Endocrinology

Abstract

SUMMARY: Cardiac systolic time intervals were studied in ten patients with primary hypo‐thyroidism before and during therapy with increasing doses of oral L‐triiodo‐thyronine (L‐T3). Therapy was increased sequentially from 10, 20, 25 to 50 μg of L‐T3 daily on a monthly basis. On L‐T3, 20 to 25 μg/day, cardiac systolic time intervals and other peripheral responses to thyroid hormone including serum cholesterol concentration, serum creatine phosphokinase (CPK) activity, and basal metabolic rate had normalized. However, serum thyrotrophin (TSH) levels and peak TSH responses to thyrotrophin‐releasing hormone (TRH) remained elevated on these doses of L‐T3. As the dose of L‐T3 was increased from 20 to 50 μg/day, mean basal serum TSH levels decreased from 55 to 16 μu/ml, and the peak TSH response to TRH decreased from 243 to 58 μu/ml (P < 0.001) while systolic time intervals did not decrease further. Changing to L‐thyroxine (L‐T4) therapy at this point resulted in further suppression of TSH secretion, without significantly altering systolic time intervals or the other peripheral responses to thyroid hormone. These data suggest (a) that some biological responses to thyroid hormone were normalized on lower doses of L‐T3 than were required to normalize TSH secretion, and (b) that higher doses of L‐T3 or substituting L‐T4 therapy could suppress TSH secretion further without altering the other peripheral responses to thyroid hormone.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.1980.tb03414.x

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Compared with normal individuals with similar TSH levels, LT4-treated patients exhibit a slightly lower basal metabolic rate.

    “exhibit a slightly lower basal metabolic rate (BMR) (15,17,18)”
  • In 10 hypothyroid patients treated with increasing LT3 doses, 20-25 mcg/day normalized cardiac systolic time intervals and serum creatine phosphokinase activity but not BMR, total cholesterol, or serum TSH; increasing to 50 mcg/day decreased mean basal serum TSH from 55 to 16 μU/mL and brought all parameters within normal reference range except total cholesterol, which remained above 200 mg/dL.

    “On LT3, 20–25 mcg/day, cardiac systolic time intervals and serum creatine phosphokinase activity had normalized, but BMR, total cholesterol concentration, and serum TSH levels had not. As the dose of LT3 was increased to 50 mcg/day, mean basal serum TSH levels decreased from 55 to 16 μU/mL, bringing all parameters to within normal reference range, except for total cholesterol that remained above 2”
  • Only 50 mcg/day LT3 normalized the 24-hour-integrated serum concentration of T3, and no adverse drug reactions were reported.

    “Notably, only 50 mcg/day LT3 normalized the 24-hour-integrated serum concentration of T3; no ADRs were reported (18).”

Cited by

Sorted by citations

Authors
RIDGWAY, E. C., COOPER, D. S., WALKER, H., DANIELS, G. H., CHIN, W. W., MYERS, G., & MALOOF, F.
Affiliations
Harvard University (US)
Corresponding author
RIDGWAY, E. C.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
1980-11
Volume
13
Issue
5
Pages
479-488
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2127692335
Cited by
30
References
0
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 3 · 2014: 1
FWCI
2.06
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Philosophical Society
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
primary hypothyroidism, triiodothyronine, levothyroxine, thyroid hormone replacement, thyrotropin secretion, thyrotropin-releasing hormone stimulation, serum cholesterol, creatine kinase, basal metabolic rate, TSH suppression
MeSH terms
Adult, Aged, Cholesterol, Female, Heart, Humans, Hypothyroidism, Male, Middle Aged, Pituitary Gland, Systole, Thyrotropin, Thyroxine, Triiodothyronine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review